WHWK
Whitehawk Therapeutics, Inc.Company Information
- Company Name
- Whitehawk Therapeutics, Inc.
- CIK
- CIK0001422142
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- WHWK: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- WHWK
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-04-16
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 355,487
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 43,106,640
- Shares outstanding
- 82,886,196
- Ownership
- 52.01%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -1.70%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 85 | 35 | 38 | 38 | 145 | 228 | 29 | 31 | 41 | 54 | 63 | 69 | ||||||
| Short Term Investments | 105 | 88 | 108 | 125 | 32 | 3 | 19 | 32 | 37 | 34 | 46 | 51 | ||||||
| Accounts Receivable Net Current | - | - | 0 | 0 | 0 | 0 | 6 | 7 | 6 | 5 | 5 | 6 | ||||||
| Inventory Net | - | - | 0 | 0 | 0 | 0 | 5 | 5 | 6 | 6 | 6 | 4 | ||||||
| Prepaid Expense And Other Assets Current | 2 | 3 | 3 | 2 | 1 | 2 | 3 | 3 | 2 | 3 | 4 | 4 | ||||||
| Assets Current | 192 | 126 | 149 | 165 | 179 | 233 | 61 | 77 | 93 | 103 | 125 | 133 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 6 | 6 | 6 | 5 | 4 | ||||||
| Operating Lease Right Of Use Asset | - | - | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | ||||||
| Assets | 194 | 127 | 151 | 167 | 181 | 234 | 70 | 86 | 102 | 111 | 132 | 140 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 2 | 1 | 2 | 3 | 4 | 2 | 1 | 2 | 3 | 6 | 3 | ||||||
| Accrued Liabilities Current | 10 | 9 | 14 | 8 | 5 | 9 | 15 | 14 | 14 | 11 | 14 | 12 | ||||||
| Operating Lease Liability Current | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 11 | 11 | 15 | 10 | 9 | 12 | 17 | 16 | 22 | 20 | 26 | 21 | ||||||
| Operating Lease Liability Noncurrent | - | - | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Liabilities Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | - | ||||||
| Liabilities | 11 | 11 | 15 | 10 | 9 | 12 | 18 | 17 | 23 | 21 | 27 | 21 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 575 | 492 | 489 | 487 | 484 | 481 | 385 | 383 | 381 | 378 | 374 | 371 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -392 | -375 | -353 | -330 | -312 | -260 | -333 | -314 | -302 | -287 | -269 | -253 | ||||||
| Stockholders Equity | 183 | 116 | 136 | 157 | 172 | 222 | 52 | 69 | 79 | 90 | 105 | 118 | ||||||
| Liabilities And Stockholders Equity | 194 | 127 | 151 | 167 | 181 | 234 | 70 | 86 | 102 | 111 | 132 | 140 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | ||||||
| Common Stock Shares Issued | 57 | 47 | 47 | 47 | 47 | 47 | 25 | 25 | 25 | 25 | 25 | 25 | ||||||
| Shares Outstanding | 57 | 47 | 47 | 47 | 47 | 47 | 25 | 25 | 25 | 25 | 25 | 25 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialWhitehawk Therapeutics, Inc. (WHWK) — SEC Financial Statements & Analysis
Whitehawk Therapeutics, Inc. (WHWK) is a pharmaceutical preparations company, incorporated in DE. Whitehawk Therapeutics, Inc. trades on Nasdaq as: WHWK. Whitehawk Therapeutics, Inc. (WHWK)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Whitehawk Therapeutics, Inc. carries a market cap of $379.62M, a P/E ratio of -4.76x, a P/B ratio of 2.08x, a P/S ratio of 20.96x, an enterprise value of $294.38M, and an EV/EBITDA multiple of -3.42x. On profitability, it posts a gross margin of 88.72%, an operating margin of -1601.12%, a net margin of -288.26%, a Return on Equity (ROE) of -44.98%, a Return on Assets (ROA) of -42.60%, and a Return on Invested Capital (ROIC) of -137.42%. Per share, it reports EPS of $-0.96, diluted EPS of $-0.96, free cash flow per share of $-0.84, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of 666.28% year-over-year, and EPS growth of 538.67% year-over-year. On the balance sheet, it maintains a current ratio of 17.38x, a quick ratio of 17.16x, working capital of $181.34M, a debt-to-equity ratio of 0.06x, a debt ratio of 0.06, an interest coverage ratio of -2692.87x, free cash flow of $-69.35M (TTM), and net debt of $-85.23M. Figures sourced from SEC EDGAR.
- Market Cap
- $379.62M
- P/E TTM
- -4.76x
- EPS TTM
- $-0.96
- P/B TTM
- 2.08x
- ROE TTM
- -44.98%
- ROA TTM
- -42.60%
- Debt To Equity
- 0.06x
- Free Cash Flow TTM
- $-69.35M
- Net Revenue TTM Growth 1Y
- -100.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Whitehawk Therapeutics, Inc. in?
Whitehawk Therapeutics, Inc. (WHWK) operates in the Pharmaceutical Preparations industry.
What exchange does WHWK trade on?
Whitehawk Therapeutics, Inc. (WHWK) trades on the Nasdaq.
Where is Whitehawk Therapeutics, Inc. incorporated?
Whitehawk Therapeutics, Inc. is incorporated in DE.
When was Whitehawk Therapeutics, Inc. (WHWK)'s most recent SEC filing?
Whitehawk Therapeutics, Inc. (WHWK)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is WHWK's market cap?
Whitehawk Therapeutics, Inc. (WHWK) has a market capitalization of $379.62M as of 2026-06-30.
What is WHWK's EPS (earnings per share)?
Whitehawk Therapeutics, Inc. (WHWK)'s trailing twelve month EPS is $-0.96 as of 2026-06-30.
What is WHWK's ROE (return on equity)?
Whitehawk Therapeutics, Inc. (WHWK)'s trailing twelve month Return on Equity (ROE) is -44.98% as of 2026-06-30.
What is WHWK's ROA (return on assets)?
Whitehawk Therapeutics, Inc. (WHWK)'s trailing twelve month Return on Assets (ROA) is -42.60% as of 2026-06-30.
What is WHWK's ROIC (return on invested capital)?
Whitehawk Therapeutics, Inc. (WHWK)'s trailing twelve month Return on Invested Capital (ROIC) is -137.42% as of 2026-06-30.
What is WHWK's EV/EBITDA?
Whitehawk Therapeutics, Inc. (WHWK)'s trailing twelve month EV/EBITDA is -3.42x as of 2026-06-30.